Antiplatelet therapy for patients with stable ischemic heart disease and baseline thrombocytopenia: Ask the hematologist

References

• Nikolsky E, Sadeghi HM, Effron MB, Mehran R, Lansky AJ, Na Y, Cox DA, Garcia E, Tcheng JE, Griffin JJ, et al. Impact of in-hospital acquired thrombocytopenia in patients undergoing primary angioplasty for acute myocardial infarction. Am J Cardiol 2005;96:474–481
   PubMed Web of Science ®Google Scholar
• Berkowitz SD, Sane DC, Sigmon KN, Shavender JH, Harrington RA, Tcheng JE, Topol EJ, Califf RM. Occurrence and clinical significance of thrombocytopenia in a population undergoing high risk percutaneous coronary revascularization. Evaluation of c7E3 for the Prevention of Ischemic Complications (EPIC) Study Group. J Am Coll Cardiol 1998;32:311–319
   PubMed Web of Science ®Google Scholar
• Sideris SK, Bonios MJ, Eftihiadis EE, Melexopoulou CA, Mousiama TA, Diplaris KT, Kogias JS. Severe thrombocytopenia after heparin therapy in a patient with unstable angina and recent stent implantation. Hellenic J Cardiol 2005;46:242–246
   PubMedGoogle Scholar
• Merlini PA, Rossi M, Menozzi A, Buratti S, Brennan DM, Moliterno DJ, Topol EJ, Ardissino D. Thrombocytopenia caused by abciximab or tirofiban and its association with clinical outcome in patients undergoing coronary stenting. Circulation 2004;109:2203–2206
   PubMed Web of Science ®Google Scholar
• Shenoy C, Harjai K. Thrombocytopenia following Percutaneous Coronary Intervention. J Interven Cardiol 2011;24:15–26
   PubMed Web of Science ®Google Scholar
• Overgaard CB, Ivanov J, Seidelin PH, Todorov M, Mackie K, Dzavík V. Thrombocytopenia at baseline is a predictor of inhospital mortality in patients undergoing percutaneous coronary intervention. Am Heart J 2008;156:120–124
   PubMed Web of Science ®Google Scholar
• Akhtari M. When to Treat Myelodysplastic Syndromes. Oncology 2011;25:480–486
   PubMed Web of Science ®Google Scholar
• Stasi R. Immune thrombocytopenic purpura: The treatment paradigm. Eur J Haematol 2009;82(Suppl. 71):13–19
   PubMed Web of Science ®Google Scholar
• Guyatt GH, Norris SL, Schulman S, Hirsh J, Eckman MH, Akl EA, Crowther M, Vandvik PO, Eikelboom JW, McDonagh MS, et al. Methodology for the development of antithrombotic therapy and prevention of thrombosis guidelines: Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012;141(2 Suppl):53S–70S
   PubMed Web of Science ®Google Scholar
• Valgimigli M, Campo G, Monti M, Vranckx P, Percoco G, Tumscitz C, Castriota F, Colombo F, Tebaldi M, Fucà G, et al. Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: A randomized multicenter trial. Clinical Perspective Circulation 2012;125:2015–2026
   PubMed Web of Science ®Google Scholar
• Russo A, Cannizzo M, Ghetti G, Barbaresi E, Filippini E, Specchia S, Branzi A. Idiopathic thrombocytopenic purpura and coronary artery disease: Comparison between coronary artery bypass grafting and percutaneous coronary intervention. Interact CardioVasc Thorac Surg 2011;13:153–157
   PubMed Web of Science ®Google Scholar
• Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007;357:2001–2015
   PubMed Web of Science ®Google Scholar
• Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, Horrow J, Husted S, James S, Katus H. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009;361:1045–1057
   PubMed Web of Science ®Google Scholar
• Carbajal EV, Deedwania P. Role of medical versus interventional strategies to prevent coronary events in patients with stable coronary artery disease. Cardiol Clin 2011;29:157–165
   PubMed Web of Science ®Google Scholar
• Fihn SD, Gardin JM, Abrams J, Berra K, Blankenship JC, Dallas AP, Douglas PS, Foody JM, Gerber TC, Hinderliter AL, et al. 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation 2012;126:e354–e471
   PubMed Web of Science ®Google Scholar
• Simoons ML, Windecker S. Chronic stable coronary artery disease: Drugs vs. revascularization. Eur Heart J 2010;31:530–541
   PubMed Web of Science ®Google Scholar
• Magro M, Garg S, Serruys PW. Revascularization treatment of stable coronary artery disease. Expert Opin Pharmacother 2011;12:195–212
   PubMed Web of Science ®Google Scholar
• Tandar A, Boden E. Evolving concepts in selecting optimal strategies for the management of patients with stable coronary disease: Pharmacologic or revascularization therapy. Current Opinion in Cardiology 2009;24:591–595
   PubMed Web of Science ®Google Scholar